• Aucun résultat trouvé

Prise en charge de l'infarctus du myocarde à la phase aigue : à propos de 70 cas

N/A
N/A
Protected

Academic year: 2021

Partager "Prise en charge de l'infarctus du myocarde à la phase aigue : à propos de 70 cas"

Copied!
151
0
0

Texte intégral

Loading

Figure

Figure n°1 :   Nouvelle classification des syndromes coronariens aigus. relation clinique,
Tableau II : Topographie de l’infarctus du myocarde [36,38]
Tableau III :   Principales situations cliniques où les troponines peuvent s’élever en  l’absence d’ischémie coronarienne
Tableau IV : Les contre-indications de la thrombolyse  [81]                                           Contre-indications absolues
+7

Références

Documents relatifs

Long-term outcome in early survivors of cardiogenic shock at the acute stage of myocardial infarction: a landmark analysis from the French registry of Acute ST-elevation

Cross-genera sets of markers may allow the comparison of genetic polymorphism between several Brassicaceae at genes putatively involved in traits of interest, such as heavy-

First, in order to differentiate the impact of human rights stand- ards in PTAs from a countries’ general commitment to international human rights agreements, we include information

On SPIO technique both readers were asked to match the signal intensity of the treated HCC relative to sur- rounding liver parenchyma on T2-weighted images before and after

L’administration de médicaments intraveineux en Y est la méthode la plus utilisée en milieu hospitalier. Toutefois, des données de compatibilité entre médicaments intraveineux ne

This book is successfully organized into 8 sections that present the diagnosis of pathological parasites in a context that promotes the best patient care and clinical outcome.. The

However, in a symbolic regression tree analysis using hospital pathways as statistical units, the type of pathway followed was the key predictor variable, showing in particular

Figure 1) Comparison of 30-day mortality outcome in patients treated with glucose-insulin-potassium (GIK) therapy. ORs and 95% CIs are presented for individual studies and